Immunicum CEO purchases shares in the Company

Press release

GOTHENBURG, Sweden, December 2, 2016 – Immunicum AB (publ; First North Premier: IMMU.ST), a biopharmaceutical company striving to develop sophisticated, safe and efficacious therapeutic cancer treatments inducing powerful and long lasting immune responses, today announced that CEO, Carlos de Sousa has purchased 23,686 shares in Immunicum AB.

“Immunicum is in an exciting phase going forward. For me it is natural to ensure that I am not only the CEO, but also a shareholder in the company” said Dr. Carlos de Sousa, CEO of Immunicum. 

About Immunicum AB (publ)
Immunicum AB (publ) develops cancer immune primers for the treatment of tumor diseases. A phase II clinical trial for the Company’s most advanced product – INTUVAX® against kidney cancer – has been initiated. The project portfolio contains additional clinical phase I/II studies in liver cancer and in
gastrointestinal stromal tumors (GIST). Immunicum is listed on First North Premier.

The company’s Certified Adviser is Redeye AB
Ph: + 46 8 545 013 31

Keep reading

Immunicum’s nomination committee for the Annual General Meeting 2017 appointed